Sanofi strikes $805m deal with Principia Biopharma for multiple sclerosis drug development

Sanofi and Principia Biopharma have announced a significant partnership to develop and commercialize PRN2246, a promising oral drug candidate for multiple sclerosis (MS) and other ... Read More